These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 31834326)

  • 1. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
    Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
    Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
    J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study].
    Barrios V; Escobar C; Lobos JM; Polo J; Vargas D
    Semergen; 2017 Oct; 43(7):477-485. PubMed ID: 28029563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
    Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
    [No Abstract]   [Full Text] [Related]  

  • 12. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study.
    Denas G; Fedeli U; Gennaro N; Ferroni E; Corti MC; Pengo V
    J Cardiovasc Med (Hagerstown); 2020 Jun; 21(6):415-419. PubMed ID: 32355064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
    De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
    J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
    Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
    Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.